Personalized management of dyslipidemias in patients with diabetes—it is time for a new approach (2022)

Dyslipidemia in patients with type 2 diabetes (DMT2) is one of the worst controlled worldwide, with only about 1/4 of patients being on the low-density lipoprotein cholesterol (LDL-C) target. There are many reasons of this, including physicians’ inertia, including diabetologists and cardiologists, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Banach, Maciej, Surma, Stanisław, Reiner, Zeljko, Katsiki, Niki, Penson, Peter E., Fras, Zlatko, Sahebkar, Amirhossein, Paneni, Francesco, Rizzo, Manfredi, Kastelein, John
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706947/
https://www.ncbi.nlm.nih.gov/pubmed/36443827
http://dx.doi.org/10.1186/s12933-022-01684-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9706947/
https://www.ncbi.nlm.nih.gov/pubmed/36443827
http://dx.doi.org/10.1186/s12933-022-01684-5

Ejemplares similares